eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
4/2009
vol. 13
 
Share:
Share:
more
 
 
abstract:
Review paper

Capecitabine in palliative chemotherapy of colorectal cancer – efficacy and toxicity

Rafał Stec
,
Lubomir Bodnar
,
Cezary Szczylik

Współczesna Onkologia (2009) vol. 13; 4 (167-176)
Online publish date: 2009/09/15
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Capecitabine is an oral carbamate of fluoropyrimidine, precursor of 5-fluorouracil. Activation of capecitabine proceeds by way of three steps. The final step of conversion to 5-fluorouracil is catalyzed by thymidine phosphorylase, which is four times more active in tumour cells than in healthy tissue. In the treatment of colorectal cancer are used the following schemas of palliative chemotherapy containing capecitabine: monotherapy of capecitabine, XELIRI (capecitabine + irinotecan), XELOX (capecitabine + oxaliplatin), CAPLRI/Bev (bevacizumab + capecitabine/irinotecan), CAPOX/Bev (bevacizumab + capecitabine/ /oxaliplatin). In the presented clinical trials, the effectiveness of an oral capecitabine in combination with irinotecan or oxaliplatin is comparable to intravenous schemas FOLFIRI and FOLFOX, with a slightly better safety profile. In conclusion, an oral capecitabine in monotherapy or combination is an interesting alternative to intravenous chemotherapy and could be considered in the treatment of metastatic colorectal cancer.
keywords:

colorectal cancer, palliative chemotherapy, capecitabine, oxaliplatin, irinotecan

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe